183 related articles for article (PubMed ID: 31472039)
1. Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial.
Takagi K; Blet A; Levy B; Deniau B; Azibani F; Feliot E; Bergmann A; Santos K; Hartmann O; Gayat E; Mebazaa A; Kimmoun A
Eur J Heart Fail; 2020 Feb; 22(2):279-286. PubMed ID: 31472039
[TBL] [Abstract][Full Text] [Related]
2. Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics.
Deniau B; Rehfeld L; Santos K; Dienelt A; Azibani F; Sadoune M; Kounde PR; Samuel JL; Tolpannen H; Lassus J; Harjola VP; Vodovar N; Bergmann A; Hartmann O; Mebazaa A; Blet A
Eur J Heart Fail; 2020 Feb; 22(2):290-299. PubMed ID: 31472040
[TBL] [Abstract][Full Text] [Related]
3. Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study.
Blet A; Deniau B; Santos K; van Lier DPT; Azibani F; Wittebole X; Chousterman BG; Gayat E; Hartmann O; Struck J; Bergmann A; Antonelli M; Beishuizen A; Constantin JM; Damoisel C; Deye N; Di Somma S; Dugernier T; François B; Gaudry S; Huberlant V; Lascarrou JB; Marx G; Mercier E; Oueslati H; Pickkers P; Sonneville R; Legrand M; Laterre PF; Mebazaa A;
Crit Care; 2021 Feb; 25(1):61. PubMed ID: 33588925
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes.
Wenzl FA; Bruno F; Kraler S; Klingenberg R; Akhmedov A; Ministrini S; Santos K; Godly K; Godly J; Niederseer D; Manka R; Bergmann A; Camici GG; von Eckardstein A; Stähli B; Muller O; Roffi M; Räber L; Lüscher TF
Eur Heart J; 2023 Oct; 44(38):3859-3871. PubMed ID: 37632743
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl Amino-Peptidase 3 (DPP3) as an Early Marker of Severity in a Patient Population with Cardiogenic Shock.
Innelli P; Lopizzo T; Paternò G; Bruno N; Radice RP; Bertini P; Marabotti A; Luzi G; Stabile E; Di Fazio A; Pittella G; Paternoster G
Diagnostics (Basel); 2023 Apr; 13(7):. PubMed ID: 37046568
[TBL] [Abstract][Full Text] [Related]
6. High Circulating Dipeptidyl Peptidase 3 Predicts Mortality and Need for Organ Support in Cardiogenic Shock: An Ancillary Analysis of the ACCOST-HH Trial.
Picod A; Nordin H; Jarczak D; Zeller T; Oddos C; Santos K; Hartmann O; Herpain A; Mebazaa A; Kluge S; Azibani F; Karakas M
J Card Fail; 2024 Apr; ():. PubMed ID: 38697465
[TBL] [Abstract][Full Text] [Related]
7. The value of bioactive adrenomedullin and dipeptidyl peptidase 3 to predict short-term unfavourable outcomes after cardiac surgery: A prospective cohort study.
van Lier D; Beunders R; Kox M; Pickkers P
Eur J Anaesthesiol; 2022 Apr; 39(4):342-351. PubMed ID: 35102040
[TBL] [Abstract][Full Text] [Related]
8. Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction.
Levy B; Clere-Jehl R; Legras A; Morichau-Beauchant T; Leone M; Frederique G; Quenot JP; Kimmoun A; Cariou A; Lassus J; Harjola VP; Meziani F; Louis G; Rossignol P; Duarte K; Girerd N; Mebazaa A; Vignon P;
J Am Coll Cardiol; 2018 Jul; 72(2):173-182. PubMed ID: 29976291
[TBL] [Abstract][Full Text] [Related]
9. Effects of enrichment strategies on outcome of adrecizumab treatment in septic shock:
van Lier D; Picod A; Marx G; Laterre PF; Hartmann O; Knothe C; Azibani F; Struck J; Santos K; Zimmerman J; Bergmann A; Mebazaa A; Pickkers P
Front Med (Lausanne); 2022; 9():1058235. PubMed ID: 36530868
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of circulating dipeptidyl-peptidase 3 restores cardiac function in a sepsis-induced model in rats: A proof of concept study.
Deniau B; Blet A; Santos K; Vaittinada Ayar P; Genest M; Kästorf M; Sadoune M; de Sousa Jorge A; Samuel JL; Vodovar N; Bergmann A; Mebazaa A; Azibani F
PLoS One; 2020; 15(8):e0238039. PubMed ID: 32853284
[TBL] [Abstract][Full Text] [Related]
11. In-hospital mortality and organ failure after open and endovascular thoraco-abdominal aortic surgery can be predicted by increased levels of circulating dipeptidyl peptidase 3.
Gombert A; Barbati M; Kotelis D; Simon TP; Breuer T; Hartmann O; Santos K; Bergmann D; Schulte J; Marx G; Jacobs M; Stoppe C
Eur J Cardiothorac Surg; 2021 Apr; 59(4):750-757. PubMed ID: 33236058
[TBL] [Abstract][Full Text] [Related]
12. Circulating dipeptidyl peptidase-3 at admission is associated with circulatory failure, acute kidney injury and death in severely ill burn patients.
Dépret F; Amzallag J; Pollina A; Fayolle-Pivot L; Coutrot M; Chaussard M; Santos K; Hartmann O; Jully M; Fratani A; Oueslati H; Cupaciu A; Benyamina M; Guillemet L; Deniau B; Mebazaa A; Gayat E; Farny B; Textoris J; Legrand M;
Crit Care; 2020 Apr; 24(1):168. PubMed ID: 32321571
[TBL] [Abstract][Full Text] [Related]
13. Associations of dipeptidyl-peptidase 3 with short-term outcome in a mixed admission ICU-cohort.
van Lier D; Beunders R; Kox M; Pickkers P
J Crit Care; 2023 Dec; 78():154383. PubMed ID: 37482013
[TBL] [Abstract][Full Text] [Related]
14. Circulatory dipeptidyl peptidase 3 (cDPP3) is a potential biomarker for early detection of secondary brain injury after aneurysmal subarachnoid hemorrhage.
Neumaier F; Stoppe C; Veldeman M; Weiss M; Simon T; Hoellig A; Marx G; Clusmann H; Albanna W
J Neurol Sci; 2021 Mar; 422():117333. PubMed ID: 33549902
[TBL] [Abstract][Full Text] [Related]
15. Plasma proenkephalin A 119-159 and dipeptidyl peptidase 3 on admission after cardiac arrest help predict long-term neurological outcome.
Thorgeirsdóttir B; Levin H; Spångfors M; Annborn M; Cronberg T; Nielsen N; Lybeck A; Friberg H; Frigyesi A
Resuscitation; 2021 Jun; 163():108-115. PubMed ID: 33930500
[TBL] [Abstract][Full Text] [Related]
16. Elevated Plasma Bioactive Adrenomedullin and Mortality in Cardiogenic Shock: Results from the OptimaCC Trial.
Takagi K; Levy B; Kimmoun A; Miró Ò; Duarte K; Asakage A; Blet A; Deniau B; Schulte J; Hartmann O; Cotter G; Davison BA; Gayat E; Mebazaa A
J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640526
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure.
Boorsma EM; Ter Maaten JM; Damman K; van Veldhuisen DJ; Dickstein K; Anker SD; Filippatos G; Lang CC; Metra M; Santos K; Voors AA
Eur J Heart Fail; 2021 Jun; 23(6):947-953. PubMed ID: 33742751
[TBL] [Abstract][Full Text] [Related]
18. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial.
; Alexander JH; Reynolds HR; Stebbins AL; Dzavik V; Harrington RA; Van de Werf F; Hochman JS
JAMA; 2007 Apr; 297(15):1657-66. PubMed ID: 17387132
[TBL] [Abstract][Full Text] [Related]
19. Circulating dipeptidyl peptidase 3 on intensive care unit admission is a predictor of organ dysfunction and mortality.
Frigyesi A; Lengquist M; Spångfors M; Annborn M; Cronberg T; Nielsen N; Levin H; Friberg H
J Intensive Care; 2021 Aug; 9(1):52. PubMed ID: 34429159
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase 3, a biomarker in cardiogenic shock and hopefully much more.
Magliocca A; Omland T; Latini R
Eur J Heart Fail; 2020 Feb; 22(2):300-302. PubMed ID: 31840335
[No Abstract] [Full Text] [Related]
[Next] [New Search]
